Patients with diabetes often face a brutal “syndemic”—a tangled web of chronic illness, Relentless nerve pain (neuropathy), and severe depression, all fueled by a common biological enemy: metabolic inflammation and Advanced Glycation End-products (AGEs). In this episode, we explore why ketamine, with its rapid antidepressant and non-opioid painkilling properties, looks like the perfect “two birds, one stone” solution on paper.

But in practice, it requires walking a high-stakes “metabolic tightrope.” We dive into the complex risks:

The solution? A move away from “one-size-fits-all” medicine toward Model-Informed Precision Dosing—using a patient’s kidney function, liver health, and genetics to calculate the perfect, safe dose.

Reference:

Sukhram, S. D., Sanchez, M., Anidugbe, A., Kupa, B., Edwards, V. P., Zia, M., & Yilmaz, G. (2026). Ketamine in diabetes care: Metabolic insights and clinical applications. Pharmaceutics, 18(1), 81. https://doi.org/10.3390/pharmaceutics18010081

The post Ketamine and Diabetes – The Metabolic Tightrope appeared first on Talking Ketamine Podcast.